A5048566051- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- CAR-T cell therapy research
- CNS Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Cutaneous lymphoproliferative disorders research
- Monoclonal and Polyclonal Antibodies Research
- Immunodeficiency and Autoimmune Disorders
- Polyomavirus and related diseases
- T-cell and Retrovirus Studies
- Glioma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Protein Degradation and Inhibitors
- Immune Cell Function and Interaction
- Neutropenia and Cancer Infections
- Advanced Breast Cancer Therapies
- Sarcoma Diagnosis and Treatment
- Medical Imaging Techniques and Applications
- Chronic Myeloid Leukemia Treatments
- Fungal Infections and Studies
- Multiple Myeloma Research and Treatments
- Bacterial Identification and Susceptibility Testing
- Glycosylation and Glycoproteins Research
- Nail Diseases and Treatments
Institut Català d'Oncologia
2016-2025
Universitat de Barcelona
2016-2025
Institut d'Investigació Biomédica de Bellvitge
2016-2025
Duran i Reynals Hospital
2015-2024
Bellvitge University Hospital
1995-2022
Institut Català d'Ornitologia
2014-2019
European Organisation for Research and Treatment of Cancer
2018
Ajuntament de L’Hospitalet
2013-2017
Spanish Oncology Genitourinary Group
2004-2015
Johns Hopkins University
2012
MYC alterations influence the survival of patients with diffuse large B-cell lymphoma. Most studies have focused on translocations but there is little information regarding impact numerical and protein expression. We analyzed genetic expression MYC, BCL2, BCL6, MALT1 in 219 cases rearrangement occurred as sole abnormality (MYC single-hit) 3% cases, concurrent BCL2 and/or BCL6 rearrangements double/triple-hit) 4%, amplifications 2% gains 19%. single-hit, double/triple-hit amplifications, not...
Survival in mycosis fungoides (MF) is varied and may be poor. The PROCLIPI (PROspective Cutaneous Lymphoma International Prognostic Index) study a web-based data collection system for early-stage MF with legal data-sharing agreements permitting international collaboration rare cancer complex pathology. Clinicopathological must 100% complete in-built intelligence the database ensures accurate staging.
Tafasitamab (MOR208), an Fc-modified, humanized, anti-CD19 monoclonal antibody, combined with the immunomodulatory drug lenalidomide was clinically active a good tolerability profile in open-label, single-arm, phase II L-MIND study of patients relapsed/refractory diffuse large B-cell lymphoma (DLBCL) ineligible for autologous stem-cell transplantation. To assess long-term outcomes, we report updated analysis ≥35 months’ follow-up. Patients were aged >18 years, had received one to three...
Here, we evaluate the sensitivity and specificity of a new 11-parameter flow cytometry (FCM) approach versus conventional cytology (CC) for detecting neoplastic cells in stabilized CSF samples from newly diagnosed aggressive B-cell non-Hodgkin's lymphoma (B-NHL) at high risk CNS relapse, using prospective, multicentric study design.Moreover, compared distribution different subpopulations leukocytes clinico-biologic characteristics CSF+ CSF-, patients, an attempt to define algorithms useful...
Background The role of re-treatment with rituximab in aggressive B-cell lymphomas still needs to be defined. This study evaluated the influence prior exposure on response rates and survival patients diffuse large lymphoma treated plus etoposide, cytarabine, cisplatinum methylprednisolone (R-ESHAP).Design Methods We retrospectively analyzed 163 relapsed or refractory who received R-ESHAP as salvage therapy a curative purpose. Patients were divided into two groups according whether had been...
Genome studies of diffuse large B-cell lymphoma (DLBCL) have revealed a number somatic mutations and structural alterations. However, the clinical significance these alterations is still not well defined. In this study, we integrated analysis targeted next-generation sequencing 106 genes genomic copy (CNA) in 150 DLBCL. The clinically significant findings were validated an independent cohort 111 patients. Germinal center activated DLBCL had differential profile mutations, altered pathogenic...
Background Diffuse large B-cell lymphoma is a clinically and molecularly heterogeneous disease. Gene expression profiling studies have shown that the tumor microenvironment affects survival angiogenesis-related signature prognostically unfavorable. The contribution of histopathological microvessel density to in diffuse lymphomas treated with immunochemotherapy remains unknown. purpose this study assess prognostic impact two independent series patients immunochemotherapy.Design Methods One...
The need for an individualized management of indolent clinical forms in mantle cell lymphoma (MCL) is increasingly recognized. We hypothesized that a tailored treatment with ibrutinib combination rituximab (IR) could obtain significant responses these patients.This multicenter single-arm, open-label, phase II study two-stage design conducted 12 Spanish GELTAMO sites (ClinicalTrials.gov identifier: NCT02682641). Previously untreated MCL patients defined by the following criteria were...
We prospectively studied 485 episodes of bacteremia in neutropenic patients with cancer. Viridans streptococci caused a total 88 (18%). Ten (11%) these cases were associated serious complications: acute respiratory distress syndrome (ARDS) plus septic shock (5 cases), ARDS (3), and (2). Streptococcus mitis was the species most frequently isolated (7 10 episodes). Four viridans showed diminished susceptibility to penicillin (MICs ranged from 0.25 4 µg/mL), 5 strains resistant ceftazidime 2...
The frequency of gastrointestinal (GI) tract involvement in mantle cell lymphoma (MCL) at diagnosis is reported to be below 30%. To investigate the actual GI by MCL, upper and lower endoscopy was prospectively performed on 13 untreated MCL patients diagnosis. Multiple biopsies from endoscopically normal abnormal gastric colonic mucosa were studied with immunohistochemistry (IHC) for CD20, CD5, cyclin D1, as well fluorescence situ hybridization (FISH) t(11;14) polymerase chain reaction (PCR)...
The elective treatment of patients with post-transplant lymphoproliferative disorders is controversial. purpose this trial was to evaluate the efficacy extended doses rituximab adapted response in after solid organ transplantation.This a prospective, multicenter, phase II trial. Patients were treated reduction immunosuppression and four weekly infusions rituximab. Those who did not achieve complete remission (CR) received second course infusions. primary end-point study CR rate.Thirty-eight...
The addition of monoclonal antibodies to chemotherapy has significantly improved treatment chronic lymphocytic leukemia (CLL). Based on excellent results with the chemotherapy-only regimen fludarabine, cyclophosphamide, and mitoxantrone (FCM), we built a new chemoimmunotherapy combination--rituximab plus FCM (R-FCM). We report phase II clinical trial consisting an initial R-FCM followed by rituximab maintenance.Seventy-two untreated CLL patients age 70 years or younger received 500 mg/m(2)...
Fludarabine, cyclophosphamide, and mitoxantrone (FCM) results in a high response rate previously treated patients with chronic lymphocytic leukemia (CLL). The aim of this study was to investigate FCM as frontline therapy CLL.Sixty-nine under the age 65 years active CLL were treated. Patients received six cycles fludarabine 25 mg/m(2) i.v. x 3 days, cyclophosphamide 200 6 1 day. Treatment outcome correlated clinical biological variables. significance eradicating minimal residual disease (MRD)...
Summary Immunochemotherapy with cyclophosphamide, adriamycin, vincristine, prednisone and rituximab (R‐CHOP) is the standard treatment in non‐immunosuppressed patients diffuse large B‐cell lymphoma (DLBCL), but its adequacy has not been definitively established human immunodeficiency virus (HIV)‐related lymphoma. This phase II trial aimed to evaluate safety efficacy of six cycles R‐CHOP HIV‐related DLBCL determine whether response highly active antiretroviral therapy (HAART) had prognostic...
// Lourdes Martín-Martín 1 , Julia Almeida Helena Pomares 2 Eva González-Barca Pilar Bravo 3 Teresa Giménez 4 Cecilia Heras 5 José-Antonio Queizán 6 Elena Pérez-Ceballos 7 Violeta Martínez 8 Natalia Alonso 9 Carlota Calvo 10 Rodolfo Álvarez 11 María Dolores Caballero 12 and Alberto Orfao Cancer Research Centre (IBMCC, USAL-CSIC), Institute for Biomedical of Salamanca (IBSAL) Department Medicine Cytometry Service (NUCLEUS Support Platform), University (USAL), Salamanca, Spain Hematology...
The benefit of intrathecal therapy and systemic rituximab on the outcome diffuse large B-cell lymphoma at risk central nervous system disease is controversial. Furthermore, effect treatment in Burkitt with occult leptomeningeal detected by flow cytometry diagnosis unknown. Untreated (n=246) (n=80) clinical having had pre-treatment cerebrospinal fluid were analyzed cytology. Spinal involvement was alone (occult) 33 (13%) 9 (11%) patients, cytology 11 (4.5%) 5 (6%) respectively. Diffuse spinal...
Abstract Mantle cell lymphoma (MCL) is a mature B‐cell neoplasm with an aggressive behavior, characterized by the t(11;14)(q13;q32). Several secondary genetic abnormalities potential role in oncogenic process have been described. Studies of large MCL series using conventional cytogenetics, and correlating proliferation survival, are scarce. We selected 145 cases at diagnosis, displaying aberrant karyotype, from centers belonging to Spanish Cooperative Group for Hematological Cytogenetics....